JWCAR201 therapy for blood cancers and lupus
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new CAR-T cell therapy called JWCAR201 for people with certain blood cancers (like large B-cell lymphoma) or autoimmune diseases (like lupus). It aims to see if this treatment can help when other treatments haven't worked or the disease is still active.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a type of blood cancer called large B-cell lymphoma that has come back or not responded to at least two prior treatments, including one with rituximab and an anthracycline.
- Your cancer has measurable tumors on a CT scan and is visible on a PET scan.
- You are in fairly good health, with a performance status of 0 or 1 (meaning you are fully active or able to do light work).
- If you have lupus, you are between 18 and 70, have had SLE for at least 6 months, and have active disease despite using steroids and other medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
This study tests a new treatment called CAR T-cell therapy for people with severe autoimmune diseases that haven't gotten better with standard treatments. The goal is to see if it can help control the disease by reprogramming your immune cells.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests a new CAR-T cell treatment called rapcabtagene autoleucel for people with active lupus or lupus nephritis that hasn't improved with at least two standard therapies. It aims to reduce disease activity and may offer a new option for hard-to-treat cases.
This trial tests a new cell therapy called JWCAR201 for people with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not responded to at least two prior treatments. The goal is to see if this treatment can help when standard options have stopped working.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.